A Greater Increase in Complement C5a Receptor 1 Level at Onset and a Smaller Decrease in Immunoglobulin G Level after Recovery in Severer Coronavirus Disease 2019 Patients: A New Analysis of Existing Data with a New Two-Tailed It/I-Test

It is important to know exactly the difference in changes in Complement C5a Receptor 1 (C5aR1) levels at onset and in Immunoglobulin G (IgG) levels after recovery between severe and non-severe coronavirus disease 2019 (COVID-19) patients to reduce the severity of the disease and prevent reinfection with severe acute respiratory syndrome coronavirus 2. We found that some of these changes in C5aR1 and IgG levels over time were dependent on their initial levels and not suitable for analysis by conventional statistical tests. We developed new t-tests that correctly examine the above changes. Our new t-test suggested a greater increase in C5aR1-levels at onset and a smaller decrease in IgG-levels after recovery in COVID-19 patients than non-COVID-19 patients, which were not detected by conventional statistical tests. Thus, the clinical trials should be analyzed with not only conventional statistical tests but also our new t-test. (1) Background: It is our purpose to identify the differences in the changes in Complement C5a receptor 1 (C5aR1) levels showing the degree of inflammation at onset and Immunoglobulin G (IgG) levels showing the extent of survival of the virus fragments after recovery between coronavirus disease 2019 (COVID-19) and pneumonia coronavirus disease (non-COVID-19) for saving patients’ lives. (2) Methods: First, the studies showing these markers’ levels in individual patients before and after the passage of time were selected from the PubMed Central[sup.®] databases with the keywords (((COVID-19) AND individual) NOT review) AND C5a/IgG. Then, no changes in these markers’ levels with conventional analyses were selected from the studies. Finally, the no changes were reexamined with our new two-tailed t-test using the values on the regression line between initial levels and changed levels instead of the mean or median of changed levels as the expected values of changed levels. (3) Results: Not conventional analyses but our new t-test suggested a greater increase in C5aR1-levels at onset and a smaller decrease in IgG-levels after recovery in COVID-19 patients than non-COVID-19 patients. (4) Conclusion: Our new t-test also should be used in clinics for COVID-19 patients.